Patent classifications
C07D498/04
HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
The invention provides new heterocyclic compounds having the general formula (I)
##STR00001##
wherein A, L, X, m, n, R.sup.1 and R.sup.2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
The invention provides new heterocyclic compounds having the general formula (I)
##STR00001##
wherein A, L, X, m, n, R.sup.1 and R.sup.2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
##STR00001##
ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, where the substituents are as defined herein. Pharmaceutical compositions including the same and method of using the same are also described.
##STR00001##
INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
Provided herein are indole compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease
Fluoroalkyl-oxadiazoles and uses thereof
Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: ##STR00001##
or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
Proteasome inhibitors
Unique compounds useful for inhibiting a proteasome in a cell, pharmaceutical compositions and methods of their use are provided herein.
Condensed ring compounds having dopamine D3 receptor antagonistic effect
Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)′: ##STR00001##
wherein A is S or O; R.sup.1a is substituted or unsubstituted alkyloxy or the like, R.sup.2a to R.sup.2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R.sup.3 is each independently halogen or the like, r is an integer of 0 to 4, R.sup.4 is substituted or unsubstituted aromatic heterocyclyl or the like,
or a pharmaceutically acceptable salt thereof.